Synthetic Biologics(TOVX) - 2025 Q1 - Quarterly Results

Recent Highlights and Anticipated Milestones Exhibit 99.1 Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results - VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - - Closed a public offering on May 8, 2025, raising the Company's cash balance and extending its cash runway into the first quarter of 2026 - Rockville, MD, May 14, 2025 – Theriva™ Biologics (NYSE American: TOVX), a diversified clinica ...